ITIH4 and HIV infectious disease: The RV144 study conducted in Thailand, with a canarypox-vectored prime (vCP1521) followed by a protein vaccine boost with the gp120 AIDSVAX B/E vaccine, is the only HIV vaccine study thus far to show some protection [vaccine efficacy 31.2% (95% CI, 1.1 to 52.1; P = 0.04)] against HIV infection [22].